Creative BioTherapeutics Named 2026 Prix Galien USA Best Startup Award Nominee

Creative BioTherapeutics has been officially named a 2026 Prix Galien USA nominee in the Best Startup category, recognizing the company's commitment to solving the critical challenges of cancer recurrence and treatment resistance. This nomination highlights the development of their lead investigational biologic, CBT300, which aims to target the complex mechanisms that allow malignant cells to survive therapeutic pressure and evade the immune system.

Founded by Dr. Anita Davidson and Dr. Don Davidson, the company bridges the gap between clinical experience and advanced drug discovery. By focusing on the biological pathways responsible for metastasis, the team seeks to provide new, meaningful answers for patients facing the devastating reality of cancer returning after treatment. The nomination serves as an important external validation of their rigorous scientific approach as they prepare for commercial-scale production and future clinical evaluation.

The company recently achieved a significant regulatory milestone, securing FDA feedback that supports an alternative, cost-effective safety validation program for CBT300. By avoiding unnecessary animal toxicity studies, Creative BioTherapeutics is efficiently advancing toward its Investigational New Drug filing. As the team moves forward, they remain dedicated to the patient-first mission that inspired the creation of their platform, ensuring that every scientific step is taken with urgency and responsibility.